Trial Profile
A Phase I Single-Center, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8203
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Otaplimastat (Primary)
- Indications Stroke
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Shin Poong Pharmaceutical
- 20 Jul 2020 Status changed from not yet recruiting to completed.
- 02 Apr 2014 New trial record